ClinicalTrials.gg
RecruitingNCT07234903EIGERUpdated Apr 21, 2026

ARC-IM Therapy To Support and Promote Recovery of Ambulatory Functions in People With Subacute and Chronic Spinal Cord Injury

An interventional study of ARC-IM Therapy in Spinal Cord Injury, SCI and SCI - Spinal Cord Injury, sponsored by Ecole Polytechnique Fédérale de Lausanne. Recruiting at 2 sites in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Ecole Polytechnique Fédérale de Lausanne · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Spinal Cord Injuries with a site in Switzerland — 25 open to participants now, 31 under way, none of them phase 3. Spinal Cord Injuries · Switzerland.

Planned enrollment
52nd of 72
12 · median 21
Started
2026
with 7 others
No phase
59 of 111
18 open now
Primary completion
2032-04
later than 30 of 30 live
Registered
104th of 111
by date
Lead sponsor
8 of 111
Ecole Polytechnique Fédérale de Lausanne

Among the 111 studies in Spinal Cord Injuries with a site in Switzerland, this one is the 52nd largest by planned enrollment of the 72 interventional ones that give a count, is one of 8 that started in 2026, is one of 59 with no phase, reaches primary completion later than 30 of the 30 other live ones, and was the 104th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

25 of the 111 studies in Spinal Cord Injuries with a site in Switzerland are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Spinal Cord Injuries with a site in Switzerland, or all of them as a file.
02

Study summary

The EIGER study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support and promote recovery of ambulatory functions, such as walking, in people with subacute and chronic spinal cord injury.

03

Conditions studied

  • Spinal Cord Injury
  • SCI
  • SCI - Spinal Cord Injury
  • Subacute Spinal Cord Injury
  • Chronic Spinal Cord Injury
  • Spinal Cord Injury (SCI)

Keywords

  • SCI
  • Spinal Cord Injury
  • Epidural Electrical Stimulation
  • Spinal Cord Stimulation
  • ARC-IM Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be at least 18 years old and no older than 65 years old at the time of enrollment.
  2. Must be graded A, B, C, or D in the ASIA Impairment Scale (AIS).
  3. Must have a SCI level at T10 or higher as determined by ISNCSCI, with the region extending 6 cm above the tip of the conus remaining anatomically intact as determined by MRI.
  4. Must have sustained their injury either less than 6 weeks prior to baseline (Group "Subacute SCI"), or more than 1 year prior to enrollment (Group "Chronic SCI").
  5. Must be suffering from a SCI due to trauma.
  6. Must have a stable medical, physical and psychological condition as considered by the investigators and the delegated specialists.
  7. Must have residual upper limb function to use the arms for weight bearing support (as determined by functional demonstration).
  8. Must be able to understand and interact with the study team in German, French or English.
  9. Must agree to comply in good faith with all conditions of the study and to attend all scheduled appointments.
  10. Must provide as documented by signature prior to any study-related procedures.
  11. Must have an acceptable or highly effective method of for women of childbearing capacity.

Exclusion criteria

Exclusion Criteria:

  1. Must not be pregnant nor breastfeeding.
  2. Must not have brain damage.
  3. Must not have a history of epilepsy
  4. Must not have participated in another clinical study using drugs or medical devices within the 30 days preceding and during the present study.
  5. Must not have previously been injected with stem cells in the spinal cord.
  6. Must not have any diseases and conditions that would increase the morbidity and mortality of SCI surgery.
  7. Must not require ventilator support.
  8. Must not have any existing to mobility functions (e.g., unhealed bone fractures, central nervous system disorder, peripheral nerve disorder, etc.).
  9. Must not suffer from SCI from other etiology than trauma (ischemic, tumoral, , etc.).
  10. Must not have any anatomical limitations in the implantation area as judged by the investigators (e.g., spinal stenosis, limiting protrusions, post-traumatic bone damage at area of implantation).
  11. Must not require the use of an intrathecal baclofen pump.
  12. Must not have any active implanted devices.
  13. Must not have any other conditions that would make the subject unable to participate in testing in the judgment of the investigators (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.).
  14. Must not be the investigator him/herself, his/her family members, employees or other dependent persons.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Subacute SCI

    Participants having sustained the injury less than 6 weeks prior to baseline (subacute). Participants will be provided with the ARC-IM Therapy.

    Device: ARC-IM Therapy

  • Experimental
    Chronic SCI

    Participants having sustained the injury more than 1 year prior to enrollment (chronic). Participants will be provided with the ARC-IM Therapy.

    Device: ARC-IM Therapy

Interventions

  • DeviceARC-IM Therapy

    All participants will be treated with ARC-IM Therapy. The ARC-IM Lumbar System is intended to deliver electrical impulses to the lumbosacral region of the spinal cord to support ambulatory functions in people with SCI.

06

What researchers measure

Primary outcomes

  1. Occurrence of Serious Adverse Events and Adverse Events that are deemed related or possibly related to the study procedure or to ARC-IM Therapy, from implantation up to the end of the study.

    Assess the preliminary safety of ARC-IM Therapy in participants with subacute and chronic SCI.

    Time frame: Continuously throughout the study (up to 6 years)

Secondary outcomes

  1. American Spinal Injury Association (ASIA) International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI)

    The ASIA ISNCSCI is a clinical examination used to assess the motor and sensory impairment and severity of a spinal cord injury.

    Time frame: At Eligibility, and at 6 weeks, 16 weeks, 42 weeks post-surgery

  2. 10-Meter Walk Test (10MWT)

    The 10MWT assesses walking speed in meters per second over a short duration. It measures the time taken by the subjects to walk 10 meters. The test will be performed twice, at self-selected and at maximum velocity. Participants can use their habitual assistive device. The test will be conducted both with and without stimulation.

    Time frame: At Baseline, and at 6 weeks, 16 weeks, ad 42 weeks post-surgery

  3. 6-Minute Walk Test (6MWT)

    The 6MWT assesses endurance by measuring the distance in meters a participant walks in 6 minutes. Participants can use their habitual assistive device and can take as many standing breaks as they need, but the timer will not be paused. This test will be conducted both with and without stimulation.

    Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery

  4. Timed Up and Go (TUG)

    The TUG evaluates functional mobility. Participants begin seated, then stand up, walk 3 meters, turn around, walk back, and sit down. The time taken to complete the sequence is recorded. Assistive devices may be used if necessary. The test will be conducted both with and without stimulation.

    Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery

  5. Walking Index for Spinal Cord Injury version II (WISCI II)

    The WISCI II assesses the extent and nature of assistance a person with SCI requires to walk, using an ordinal scale of 20 levels, ranging from the most severe impairment (level 0) to the least severe impairment (level 20). The level is determined based on the use of assistive devices, braces, and the physical assistance of one or more persons. The test will be conducted both with and without stimulation.

    Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery

  6. Spinal Cord Injury Functional Ambulation Inventory (SCI-FAI)

    The SCI-FAI assesses functional walking ability. It is an observational gait assessment that includes 3 key domains of walking function, where 0 is the minimum and worst outcome: gait parameters (maximum score of 20 points), assistive device (each limb scored individually - maximum score of 14 points), and temporal distance (maximum score of 5 points). The test will be conducted both with and without stimulation.

    Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery

  7. Gait Analysis

    Multifactorial gait analysis that relies on high-precision recordings of whole-body kinematics and kinetics of each gait cycle will be performed. The test will be conducted both with and without stimulation.

    Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery

  8. Goal Attainment Scale (GAS)

    The GAS is used to evaluate the participant's progress toward one or more personalized goal(s), which are individually defined by the participant. Each goal is scored on a standardized scale ranging from -2 (outcome is much less than expected) to +2 (outcome is much more than expected), allowing to assess to which extent the goal is met. The form will be completed for both with and without stimulation condition.

    Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery

  9. Berg Balance Scale (BBS)

    The BBS assesses static and dynamic balance through 14 tasks, such as standing, reaching, and turning. Each item is scored on a 5-point scale (0-4) with higher scores meaning better ability to perform the assessed activity. Item scores are then summed, with a maximum score of 56. The use of assistive devices is not allowed. The test will be conducted both with and without stimulation.

    Time frame: At Baseline, and at 6 weeks, 16 weeks, 42 weeks post-surgery

Other outcomes

  1. ARC-IM stimulation usage log

    Independent use of the ARC-IM Lumbar System by study participants will be evaluated through analysis of the ARC-IM stimulation usage log.

    Time frame: At 6 weeks, 16 weeks, 42 weeks post-surgery, and at the end of the study

  2. Integration of ARC-IM Therapy within the standard-of-care

    Integration of ARC-IM Therapy within the standard-of-care for subacute SCI will be evaluated by quantifying its use within standard clinical mobility rehabilitation procedures. This will be achieved by extracting and comparing data of the Stimulation Usage Log and Participant's Calendar Log.

    Time frame: At 6 weeks, 16 weeks, and 42 weeks post-surgery

  3. EES Evoked Muscle Response

    Effect of ARC-IM Therapy on the modulation of the spinal cord will be evaluated through electrophysiological assessments that will quantify the muscle responses to EES and adaptation of these responses over time.

    Time frame: Every 2 days during the mapping phase, and at 6 weeks, 16 weeks, and 42 weeks post-surgery

  4. Function In Sitting Test for Spinal Cord Injury (FIST-SCI)

    Effect of ARC-IM Therapy on trunk stability will be evaluated using the FIST-SCI. The FIST-SCI assesses sitting balance. It evaluates sensory, motor, proactive, reactive, and steady state balance factors based on 14 items, each scored on an ordinal scale from 0 to 4, where 0 means complete assistance is needed to perform the task successfully, and 4 means can complete the task independently and successfully. The test will be conducted both with and without stimulation.

    Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks after surgery

  5. Modified Ashworth Scale (MAS)

    Effect of ARC-IM Therapy on muscle tone will be evaluated using the MAS. The MAS assesses spasticity in a participant's upper and lower limb, by rating the resistance of a muscle to passive movement at a single joint on a 6-point nominal scale, where 0 means no increase in tone, and 5 means affected parts are rigid in flexion or extension. The clinical examination will be performed both with and without stimulation on different days at similar times. Antispastic medication and time points of test/medication intake will be documented.

    Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery

  6. Spinal Cord Assessment Tool for Spastic Reflexes (SCATS)

    Effect of ARC-IM Therapy on muscle tone will be evaluated using the SCATS. The SCATS assesses 3 types of spastic motor behaviors in SCI patients - clonus, flexor spasms, and extensor spasms. The clinical examination will be performed both with and without stimulation. Antispastic medication and start time of the test will be documented for inter-test reliability.

    Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery

  7. Spinal Cord Injury - Quality of Life Short form (SCI-QoL SF)

    Effect of ARC-IM Therapy on quality of life will be evaluated with the SCI-QoL SF. The SCI-QoL SF is a PROM for individuals with SCI. It is divided into 4 domains (emotional health, physical-medical health, social participation, physical functioning) with a selection of 22 subdomains. Each subdomain has several items. The participant rates each item with a number between 1 and 5 according to the extent to which the statement it contains applies to them. Each subdomain is scored separately. The higher the score, the higher the participant's perceived quality of life.

    Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery

  8. EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L)

    Effect of ARC-IM Therapy on quality of life for chronic SCI participants will be evaluated with the EQ-5D-5L questionnaire. The EQ-5D-5L is a PROM that describes the patient's health state for five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.

    Time frame: At Baseline, at 6 weeks, 16 weeks, and 42 weeks post-surgery, and yearly until the end of study

  9. Patient Global Impression of Change (PGI-C)

    Effect of ARC-IM Therapy on the subjective change of overall status will be evaluated with the PGI-C. The PGI-C is a single-item questionnaire to measure the change of clinical status, injury severity, or injury improvement, and evaluate the response of a condition to the given therapy. It is a 7-point scale where the participant rates his/her improvement or deterioration on a scale from "1 = very much improved" to "7 = very much worse".

    Time frame: At 6 weeks, 16 weeks, and 42 weeks post-surgery

  10. Spinal Cord Independence Measure (SCIM) III

    Effect of ARC-IM Therapy on functional independence in daily living will be evaluated with the SCIM III score. The SCIM III is a disability score that addresses functional ability in daily living in people with SCI. Three specific areas are assessed: self-care (0-20 points), respiration and sphincter management (0-40 points), and mobility (0-40 points). The form will be filled out as per stimulation use of the participant in his/her daily life activities for with or without stimulation condition. Total score ranges between 0 and 100 points, with higher scores reflecting greater independence.

    Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery

  11. System Usability Scale (SUS)

    The SUS is a standardized post-usability test questionnaire comprised of 10 Likert-scale questions used to evaluate the usability of the investigational system. To collect the SUS score, participants rate how strongly they agree or disagree with statements on a 1 (strongly disagree) to 5 (strongly agree) scale.

    Time frame: At 6 weeks, 16 weeks, and 42 weeks post-surgery

  12. EMSCI Pain Assessment Form (EPAF)

    Effect of ARC-IM Therapy on pain will be evaluated with the EPAF. The EPAF is used for classification of existing pain problems in people with SCI. The clinical assessment form consists of 12 items and follows the international guidelines and recommendations for the clinical documentation and assessment of pain in SCI. One overall form will be completed summarizing with and without stimulation condition.

    Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery

  13. Dual-Energy X-Ray Absorptiometry (DEXA)

    Effect of ARC-IM Therapy on bone mineral density will be evaluated using DEXA. Participants will lie in a supine position during the scan, following standardized protocols.

    Time frame: At Baseline and at 42 weeks post-surgery

  14. Quantitative Computed Tomography (QCT)-Scan

    Effect of ARC-IM Therapy on muscle mass will be evaluated using QCT-Scan. The QCT-Scan is used to assess muscle mass by providing high-resolution cross-sectional images of the thigh and the trunk. It allows for precise measurement of muscle volume and composition. Participants will undergo the scan in a supine position, and standardized protocols will be used to ensure consistency across time points.

    Time frame: At Eligibility and at 42 weeks post-surgery

  15. Additional User Feedback

    The Additional User Feedback is a form designed to collect qualitative feedback from participants regarding their interaction with the ARCIM Lumbar System. It includes rating items to evaluate satisfaction (from "not satisfied at all" to "very satisfied") and open-ended questions addressing ease of use, satisfaction with system components such as battery life, charging time, connection stability, and overall comfort during use.

    Time frame: At 6 weeks, 16 weeks, and 42 weeks post-surgery

07

Study locations

1 of 2 sites recruiting
  • Schweizer Paraplegiker-Zentrum (SPZ)
    Nottwil, Canton of Lucerne 6207, Switzerland
    Not yet recruiting
    • Björn Zörner, PD Dr. med. Dr. sc. nat. · Contactbjoern.zoerner@paraplegie.ch · +41 41 939 58 50
    • Björn Zörner, PD Dr. med. Dr. sc. nat. · Principal investigator
  • Centre Hospitalier Universitaire Vaudois (CHUV)
    Lausanne, Canton of Vaud 1011, Switzerland
    Recruiting
    • Jocelyne Bloch, Prof. Dr. MD · Contactjocelyne.bloch@chuv.ch · +41 79 556 29 51
    • Jocelyne Bloch, Prof. Dr. MD · Principal investigator
    • Grégoire Courtine, Prof. Dr. · Sub investigator
08

References and documents

Publications

  • Capogrosso M, Wenger N, Raspopovic S, Musienko P, Beauparlant J, Bassi Luciani L, Courtine G, Micera S. A computational model for epidural electrical stimulation of spinal sensorimotor circuits. J Neurosci. 2013 Dec 4;33(49):19326-40. doi: 10.1523/JNEUROSCI.1688-13.2013. PubMed 24305828 ↗
  • Kathe C, Skinnider MA, Hutson TH, Regazzi N, Gautier M, Demesmaeker R, Komi S, Ceto S, James ND, Cho N, Baud L, Galan K, Matson KJE, Rowald A, Kim K, Wang R, Minassian K, Prior JO, Asboth L, Barraud Q, Lacour SP, Levine AJ, Wagner F, Bloch J, Squair JW, Courtine G. The neurons that restore walking after paralysis. Nature. 2022 Nov;611(7936):540-547. doi: 10.1038/s41586-022-05385-7. Epub 2022 Nov 9. PubMed 36352232 ↗
  • Wagner FB, Mignardot JB, Le Goff-Mignardot CG, Demesmaeker R, Komi S, Capogrosso M, Rowald A, Seanez I, Caban M, Pirondini E, Vat M, McCracken LA, Heimgartner R, Fodor I, Watrin A, Seguin P, Paoles E, Van Den Keybus K, Eberle G, Schurch B, Pralong E, Becce F, Prior J, Buse N, Buschman R, Neufeld E, Kuster N, Carda S, von Zitzewitz J, Delattre V, Denison T, Lambert H, Minassian K, Bloch J, Courtine G. Targeted neurotechnology restores walking in humans with spinal cord injury. Nature. 2018 Nov;563(7729):65-71. doi: 10.1038/s41586-018-0649-2. Epub 2018 Oct 31. PubMed 30382197 ↗
  • Rowald A, Komi S, Demesmaeker R, Baaklini E, Hernandez-Charpak SD, Paoles E, Montanaro H, Cassara A, Becce F, Lloyd B, Newton T, Ravier J, Kinany N, D'Ercole M, Paley A, Hankov N, Varescon C, McCracken L, Vat M, Caban M, Watrin A, Jacquet C, Bole-Feysot L, Harte C, Lorach H, Galvez A, Tschopp M, Herrmann N, Wacker M, Geernaert L, Fodor I, Radevich V, Van Den Keybus K, Eberle G, Pralong E, Roulet M, Ledoux JB, Fornari E, Mandija S, Mattera L, Martuzzi R, Nazarian B, Benkler S, Callegari S, Greiner N, Fuhrer B, Froeling M, Buse N, Denison T, Buschman R, Wende C, Ganty D, Bakker J, Delattre V, Lambert H, Minassian K, van den Berg CAT, Kavounoudias A, Micera S, Van De Ville D, Barraud Q, Kurt E, Kuster N, Neufeld E, Capogrosso M, Asboth L, Wagner FB, Bloch J, Courtine G. Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis. Nat Med. 2022 Feb;28(2):260-271. doi: 10.1038/s41591-021-01663-5. Epub 2022 Feb 7. PubMed 35132264 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2032, 72 months later.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 72 months is above that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2025
First posted
Nov 19, 2025
StartEst.
Apr 2026
Primary completionEst.
Apr 2032
CompletionEst.
Apr 2032
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07234903
Lead sponsor
Ecole Polytechnique Fédérale de Lausanne
Responsible party
Jocelyne Bloch (Professor, Centre Hospitalier Universitaire Vaudois) — Principal investigator
First posted
Nov 19, 2025
Start date
Apr 2026 (estimated)
Primary completion
Apr 2032 (estimated)
Completion
Apr 2032 (estimated)
Last update
Apr 21, 2026

Study contacts

Jocelyne Bloch, Prof. Dr. MD
Contact
jocelyne.bloch@chuv.ch
+41 79 556 29 51
Jocelyne Bloch, Prof. Dr. MD
principal investigator · CHUV
Björn Zörner, PD Dr. med. Dr. sc. nat.
principal investigator · SPZ

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion